Authors: Cesar Luiz Boguszewski Carlos Mauricio Correa dos Santos Kelly Suga Sakamoto Lilian Cassia Marini Admar Moraes de Souza Monalisa Azevedo
Publish Date: 2011/08/17
Volume: 15, Issue: 1, Pages: 44-49
Abstract
Therapy with dopamine agonists has been associated with valvular heart disease VHD in Parkinson’s disease raising concern about the safety of these drugs In hyperprolactinemic patients the studies have mainly focused on the cardiac effects of cabergoline CBG with little information on bromocriptine BRC The aim of the present study was to evaluate the prevalence of VHD in patients with prolactinomas treated with CBG and BRC The CBG group consisted of 51 patients 37 female age 423 ± 135 years who had been taking CBG for at least 1 year mean 378 ± 213 months cumulative doses 16–12868 mg The BRC group consisted of 19 patients 14 female age 418 ± 115 years who were on BRC for at least 1 year mean 548 ± 302 months cumulative doses 46875–234788 mg The controls CTR were 59 healthy subjects matched for age sex and prevalence of arterial hypertension Participants were subjected to transthoracic echocardiography and the valvular regurgitation was graduated as absent grade 0 trace 1 mild 2 moderate 3 or severe 4 Compared to CTR trace mitral Mi regurgitation 49 vs 271 P = 002 trace tricuspid Tri regurgitation 451 vs 203 P = 00003 and mild Tri regurgitation 78 vs 0 P = 00003 were more prevalent with CBG while trace Tri regurgitation 737 vs 203 P = 00004 were more prevalent with BRC Mitral tenting area was significantly higher in CBG than in BRC and CTR None of the valvar abnormalities was associated with symptoms In conclusion patients with prolactinomas treated with either CBG or BRC showed higher prevalence of trace and mild Tri or Mi regurgitation but these findings were not clinically significant
Keywords: